🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.660
0.00 (0.00%)
At close: Nov 20, 2026, 4:00 PM EST
2.650
-0.010 (-0.38%)
After-hours: Nov 20, 2026, 7:55 PM EST

Company Description

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.

The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above.

The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.

Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Aytu BioPharma, Inc.
Aytu BioPharma logo
CountryUnited States
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees76
CEOJoshua Disbrow

Contact Details

Address:
7900 East Union Avenue, Suite 920
Denver, Colorado 80237
United States
Phone720 437 6580
Websiteaytubio.com

Stock Details

Ticker SymbolAYTU
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001385818
CUSIP Number054754858
ISIN NumberUS0547548588
Employer ID47-0883144
SIC Code2834

Key Executives

NamePosition
Joshua R. DisbrowChief Executive Officer and Director
Ryan J. Selhorn C.P.A.Chief Financial Officer, Corporate Secretary and Treasurer
Jarrett T. Disbrow Ph.D.Chief Business Officer
Greg PyszczymukaChief Commercial Officer
Margaret CabanoVice President of Operations
Dr. Gerwin Westfield Ph.D.Senior Vice President of Scientific Affairs

Latest SEC Filings

DateTypeTitle
Nov 20, 2026SC 14D9Filing
Nov 16, 2026SC TO-CFiling
Nov 16, 202610-QQuarterly Report
Nov 16, 20268-KCurrent Report
Nov 16, 2026425Filing
Nov 16, 20268-KCurrent Report
Oct 27, 2026DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 22, 2026DEF 14AOther definitive proxy statements
Sep 22, 202610-KAnnual Report
Sep 22, 20268-KCurrent Report
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides